Reviewing Zealand Pharma A/S (OTCMKTS:ZLDPF) & SEGRO (OTCMKTS:SEGXF)

Zealand Pharma A/S (OTCMKTS:ZLDPF) and SEGRO (OTCMKTS:SEGXF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Zealand Pharma A/S and SEGRO’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-191.92%	-18.17%	-15.88%
SEGRO	N/A	N/A	N/A

Valuation & Earnings

This table compares Zealand Pharma A/S and SEGRO”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$49.75 million	126.32	-$102.18 million	($1.82)	-67.03
SEGRO	$931.40 million	N/A	-$314.71 million	N/A	N/A

Zealand Pharma A/S has higher earnings, but lower revenue than SEGRO.

Analyst Recommendations

This is a summary of current ratings and target prices for Zealand Pharma A/S and SEGRO, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	0	2	0	3.00
SEGRO	0	0	0	1	4.00

Risk & Volatility

Zealand Pharma A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, SEGRO has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Summary

SEGRO beats Zealand Pharma A/S on 6 of the 9 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About SEGRO

SEGRO is a UK Real Estate Investment Trust (REIT), listed on the London Stock Exchange and Euronext Paris, and is a leading owner, manager and developer of modern warehouses and industrial property. It owns or manages 10.8 million square metres of space (116 million square feet) valued at £20.6 billion serving customers from a wide range of industry sectors. Its properties are located in and around major cities and at key transportation hubs in the UK and in seven other European countries. For over 100 years SEGRO has been creating the space that enables extraordinary things to happen. From modern big box warehouses, used primarily for regional, national and international distribution hubs, to urban warehousing (including data centres) located close to major population centres and business districts, it provides high-quality assets that allow its customers to thrive. A commitment to be a force for societal and environmental good is integral to SEGRO’s purpose and strategy. Its Responsible SEGRO framework focuses on three long-term priorities where the company believes it can make the greatest impact: Championing Low-Carbon Growth, Investing in Local Communities and Environments and Nurturing Talent. Striving for the highest standards of innovation, sustainable business practices and enabling economic and societal prosperity underpins SEGRO’s ambition to be the best property company.